Rasburicase for the treatment of tumor lysis in hematological malignancies

Expert Review of Hematology

Volumn 5, Issue 1, 2012, Pages 27-38

  Malaguarnera, Giulia ^a   Giordano, Maria ^a   Malaguarnera, Mariano ^a  

^a CANNIZZARO HOSPITAL   (Italy)

Author keywords

hematological malignancies; rasburicase; tumor lysis syndrome

Indexed keywords

ALLOPURINOL; RASBURICASE; RECOMBINANT URATE OXIDASE; URICOZYME; ALLANTOIN; SR 29142; UNCLASSIFIED DRUG; URIC ACID;

ACUTE DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANAPHYLACTIC SHOCK; ARTICLE; BRONCHOSPASM; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DYSPNEA; FEVER; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; HYPERURICEMIA; HYPOXEMIA; LYMPHOBLASTOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RASH; SINGLE DRUG DOSE; TUMOR LYSIS SYNDROME; URTICARIA; VOMITING; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG CYTOTOXICITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EMERGENCY PATIENT; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMATOLOGIC MALIGNANCY; HEMOLYSIS; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY FAILURE; LIFE EXPECTANCY; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; METHEMOGLOBINEMIA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MYELOMA; NAUSEA AND VOMITING; PATIENT IDENTIFICATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PLASMA CELL LEUKEMIA; REFRACTORY ANEMIA; REHYDRATION; RESPIRATORY DISTRESS; RISK FACTOR; SENSITIVITY ANALYSIS; SEPSIS; URIC ACID BLOOD LEVEL; URINARY EXCRETION; XANTHINURIA;

HEMATOLOGIC NEOPLASMS; HUMANS; TUMOR LYSIS SYNDROME; URATE OXIDASE; URIC ACID;

EID: 84856281462     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.73     Document Type: Article

References (105)

1. Arrambide K, Toto RD. Tumor lysis syndrome. Semin. Nephrol. 13(3), 273-280 (1993). (Pubitemid 23144159)
2. Salkowsky F. [Contributions to the knowledge of leukemia]. Virchows Arch. Pathol. Anat. 50(2), 174-177 (1870).
3. Bedrna J, Polcák J. [Actuary ureter closure after irradiation with x-rays for chronic leukemias]. Medizinische Klinik 25, 1700-1701 (1929).
4. El-Husseini A, Sabucedo A, Lamarche J, Courville C, Peguero A. Acute kidney injury associated with tumor lysis syndrome: a paradigm shift. Am. J. Emerg. Med. doi:10.1016/j. ajem.2010.12.029 (2011) (Epub ahead of print).
5. Cairo MS, Bishop M. Tumor lysis syndrome: new therapeutic strategies and classification Br. J. Hematol. 127(1), 3-11 (2004). (Pubitemid 39331101)
6. Jasek AM, Day HJ. Acute spontaneous tumor lysis syndrome. Am. J. Hematol. 47(2), 129-131 (1994). (Pubitemid 24302283)
7. Cairo MS, Coiffier B, Reiter R, Younes A. Recommendation for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert panel consensus. Br. J. Hematol. 149, 578-586 (2010).
8. Will A, Tholouli E. The clinical management of tumour lysis syndrome in hematological malignancies. Br. J. Hematol. 154(1), 3-13 (2011).
9. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high grade non-Hodgkin's lymphoma. Am. J. Med. 94(2), 133-139 (1993). (Pubitemid 23046437)
10. Tannock I. Cell kinetics and chemotherapy: a critical review. Cancer Treat. Rep. 62(8), 1117-1133 (1978). (Pubitemid 9015322)
11. Locatelli F, Rossi F. Incidence and pathogenesis of tumor lysis syndrome. In:Hyperuricemic Syndromes: Pathophysiology and Therapy (Contributions to Nephrology Volume 147). Ronco C, Rodeghiero F (Eds). S Karger AG, Basel, Switzerland, 61-68 (2005). (Pubitemid 43264985)
12. Bosly A, Sonet A, Pinkerton CR et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 98(5), 1048-1054 (2003). (Pubitemid 37022107)
13. Jeha S. Tumor lysis syndrome. Semin. Hematol. 38(4 Suppl. 10), 4-8 (2001).
14. Albright RC. Acute renal failure: a pratical update. Mayo. Clin. Proc. 76(1), 67-74 (2001). (Pubitemid 32042999)
15. Hummel M, Reiter S, Adam K, Hehlmann R, Buchheidt D. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur. J. Haematol. 80(4), 331-336 (2008). (Pubitemid 351347575)
16. Humphreys BD, Soiffer RJ, Magee CC. Renal failure associated with cancer and its treatment: an update. J. Am. Soc. Nephrol. 16, 151-161 (2005). (Pubitemid 43073167)
17. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J. Clin. Oncol. 26(16), 2767-2778 (2008).
18. Yarpuzlu AA. Areview of clinical and laboratory findings and treatment of tumor lysis syndrome. Clin. Chim. Acta 333(1), 13-18 (2003). (Pubitemid 36694823)
19. Annemans L, Moeremans K, Lamotte M et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk. Lymphoma 44(1), 77-83 (2003). (Pubitemid 36113832)
20. Wossmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/ leukemia before and after introduction of prophylactic use of urate oxidase. Ann. Hematol. 82(3), 160-165 (2003). (Pubitemid 36700996)
21. Akoz AG, Yildirim N, Engin H et al. An unusual case of spontaneous acute tumor lysis syndrome associated with acute lymphoblastic leukemia: a case report and review of the literature. Acta Oncol. 46(8), 1190-1192 (2007). (Pubitemid 350058875)
22. Konuma T, Ooi J, Takahashi S et al. Fatal acute tumor lysis syndrome following intrathecal chemotherapy for acute lymphoblastic leukemia with meningeal involvement. Intern. Med. 47(22), 1987-1988 (2008).
23. Montesinos P, Lorenzo I, Martin G et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 93(1), 67-74 (2008). (Pubitemid 351156153)
24. Chen RL, Chuang SS. Transient spontaneous remission after tumor lysis syndrome triggered by a severe pulmonary infection in an adolescent boy with acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 31(1), 76-79 (2009).
25. Choi KA, Lee JE, Kim YG et al. Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. Ann. Hematol. 88(7), 639-645 (2009).
26. Feld J, Mehta H, Burkes RL. Acute spontaneous tumor lysis syndrome in adenocarcinoma of the lung: case report. Am. J. Clin. Oncol. 23(5), 491-493 (2000). (Pubitemid 32429127)
27. Habib GS, Saliba WR. Tumor lysis syndrome after hydrocortisone treatment in metastatic melanoma: a case report and review of the literature. Am. J. Med. Sci. 323(3), 155-157 (2002).
28. Stark ME, Dyer MC, Coonley CJ. Fatal acute tumor lysis syndrome with metastatic breast carcinoma. Cancer 60(4), 762-764 (1987). (Pubitemid 17131915)
29. Tomlinson GC, Solberg LAJr. Acute tumor lysis syndrome with metastatic medulloblastoma. Acase report. Cancer 53(8), 1783-1785 (1984). (Pubitemid 14127524)
30. Michallet AS, Tartas S, Coiffier B. Optimizing management of tumor lysis syndrome in adults with hematologic malignancies. Support Cancer Ther. 2(3), 159-166 (2005).
31. Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis sindrome. Nat. Clin. Pract. Onc. 3(8), 438-447 (2006).
32. Shimada M, Johnson RJ, May WS et al. A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol. Dialys. Transplant. 24, 2960-2964 (2009).
33. Pui CH, Relling MV, Lascombes F et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 11(11), 1813-1816 (1997). (Pubitemid 27485123)
34. Wolf G, Hegewisch-Becker S, Hossfeld DK et al. Hyperuricaemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy? Am. J. Kidney Dis. 34(5), E20 (1999).
35. Coiffier B, Riouffol C. Management of tumor lysis syndrome in adults. Expert Rev. Anticancer Ther. 7(2), 233-239 (2007). (Pubitemid 46277285)
36. Malaguarnera M, Vacante M, Russo C, Dipasquale G, Gargante MP, Motta M. A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. Expert Opin. Pharmacother. 10(5), 737-742 (2009).
37. Appelbaum SJ, Mayersohn M, Dorr RT, Perrier D. Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration. Cancer Chemother. Pharmacol. 8(1), 93-98 (1982). (Pubitemid 12161620)
38. Jaeger H, Russmann D, Rasper J, Blome J. Comparative study of the bioavailability and the pharmacodynamic effect of five allopurinol preparations. Arzneimittelforschung 32(4), 438-443 (1982). (Pubitemid 12147538)
39. Andreoli SP, Clark JH, Mc Guire WA, Bergstein JM. Purine excretion during tumor lysis in children with acute lymphocytic leukaemia receveing allopurinol: relationship to acute renal failure. J. Pediatr. 109, 292-298 (1986). (Pubitemid 16032526)
40. Pession A, Barbieri E. Treatment and prevention of tumor lysis syndrome in children. Experience of Associazione Italiana Ematologia Oncologia Pediatrica. Contrib. Nephrol. 147, 80-92 (2005). (Pubitemid 43264987)
41. Jeha S, Pui CH. Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome. Contrib. Nephrol. 147, 69-79 (2005). (Pubitemid 43264986)
42. Navolanic PM, Pui CH, Larson RAet al. Elitek - rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a meeting report. Dallas, Texas, 2002. Leukemia 17(3), 499-514 (2003). (Pubitemid 36395643)
43. Pui CH, Mahmoud HH, Wiley JM et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J. Clin. Oncol. 19(3), 697-704 (2001). (Pubitemid 32119083)
44. Stapleton FB, Strother DR, Roy S 3rd et al. Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics 82(6), 863-869 (1988). (Pubitemid 19009149)
45. Bordoni V, Cal MD, Rassu M et al. Protective effect of urate oxidase on uric acid induced-monocyte apoptosis. Curr. Drug Discov. Technol. 2(1), 29-36 (2005). (Pubitemid 40488620)
46. Goldman SC, Holcenberg JS, Finklestein JZ et al. Arandomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumour lysis. Blood 97(10), 2998-3003 (2001).
47. Wu XW, Lee CC, Muzny DM, Caskey CT. Urate oxidase: primary structure and evolutionary implications. Proc. Natl Acad. Sci. USA 86(23), 9412-9416 (1989). (Pubitemid 20010436)
48. Suzuki H, Verma DP. Soybean nodule-specific uricase (Nodulin-35) is expressed and assembled into a functional tetrameric holoenzyme in Escherichia coli. Plant. Physiol. 95(2), 384-389 (1991). (Pubitemid 21913823)
49. Lotfy WA. Production of a thermostable uricase by a novel Bacillus thermocatenulatus strain. Bioresour. Technol. 99(4), 699-702 (2008). (Pubitemid 350088467)
50. Suzuki K, Sakasegawa S, Misaki H, Sugiyama M molecular cloning and expression of uricase gene from arthrobacter globiformis in Escherichia coli and characterization of the gene product. J. Biosci. Bioeng. 98(3), 153-158 (2004). (Pubitemid 39410025)
51. Li J, Chen Z, Hou L et al. High-level expression, purification, and characterization of non-tagged Aspergillus flavus urate oxidase in Escherichia coli. Protein Exp. Purif. 49(1), 55-59 (2006). (Pubitemid 44278624)
52. Yeldandi AV, Yeldandi V, Kumar S et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene 109(2), 281-284 (1991).
53. Brogard JM, Coumaros D, Franckhauser J, Stahl A, Stahl J. Enzymatic uricolysis: a study of the effect of a fungal urate-oxydase. Rev. Eur. Etud. Clin. Biol. 17(9), 890-895 (1972).
54. Scott GS, Hooper DC. The role of uric acid in protection against peroxynitrite-mediated pathology. Med. Hypotheses 56(1), 95-100 (2001). (Pubitemid 32052828)
55. Kelly SJ, Delnomdedieu M, Oliverio MI. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. J. Am. Soc. Nephrol. 12(5), 1001-1009 (2001). (Pubitemid 32378341)
56. Legoux R, Delpech B, Dumont X et al. Cloning and expression in Escherichia coli of the gene encoding Aspergillus flavus urate oxidase. J. Biol. Chem. 267(12), 8565-8570 (1992).
57. Leplatois P, Le Douarin B, Loison G. High-level production of a peroxisomal enzyme: Aspergillus flavus uricase accumulates intracellularly and is active in Saccharomyces cerevisiae. Gene 122(1), 139-145 (1992).
58. McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 26(6), 806-812 (2006). (Pubitemid 43807632)
59. Fitzpatrick DA, McGeeney KF. Antigenic independence of some microbial urate oxidases. Infect. Immun. 12(6), 1237-1241 (1975).
60. Pfrimer P, Pepe de Moraes LM, Galdino AS et al. Cloning purification, and partial characterization of Bacillus subtilis urate oxidase expressed in Escherichia coli. J. Biomed. Biotech. 674908, 1-6 (2010).
61. Oldfield V, Perry CM. Rasburicase. A review of its use in the management of anticancer therapy-induced hyperuricemia. Drugs 66(4), 529-545 (2006).
62. Bayol A, Capdevielle J, Malazzi P et al. Modification of a reactive cysteine explains differences between rasburicase and UricozymeTM, a natural Aspergillus flavus uricase. Biotechnol. Appl. Biochem. 36(Pt 1), 21-31 (2002). (Pubitemid 34864481)
63. Hummel M, Buchheidt D, Reiter S et al. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukaemia - successful treatment and prevention of TLS with low-dose rasburicase. Eur. J. Haematol. 75(6), 518-521 (2005). (Pubitemid 41687787)
64. Liu CY, Sims-McCallum RP, Schiffer CA. Asingle dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk. Res. 29(4), 463-465 (2005). (Pubitemid 40255822)
65. Hutcherson DA, Gammon DC, Bhatt MS et al. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy 26(2), 242-247 (2006). (Pubitemid 43201871)
66. Trifilio S, Gordon L, Singhal S et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant. 37(11), 997-1001 (2006).
67. Tarella C, Bono D, Zanni M et al. Intensive chemotherapy in patients with lymphoma. Management of the risk of hyperuricemia. Contrib. Nephrol. 147, 93-104 (2005). (Pubitemid 43264988)
68. Ueng S. Rasburicase (Elitek): a novel agent for tumor lysis syndrome. Proc. (Bayl. Univ. Med. Cent.) 18(3), 275-279 (2005).
69. Jeha S, Kantarjian H, Irwin D et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients final results of a multicenter compassionate use trial. Leukemia 19(1), 34-38 (2005). (Pubitemid 40090073)
70. Mahmoud HH, Leverger G, Patte C et al. Advances in the management of malignancy-associated hyperuricaemia. Br. J. Cancer 77(Suppl. 4), S8-S20 (1998).
71. Pui CH. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin. Hematol. 38(4 Suppl. 10), 13-21 (2001).
72. Ishizawa K, Ogura M, Hamaguchi M et al. Safety and efficacy of rasburicase (SR29142) in a Japanese Phase 2 study. Cancer Sci. 100(2), 357-362 (2009).
73. Cortes J, Moore JO, Maziarz RT et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter Phase 3 study. J. Clin. Oncol. 28(27), 4207-4213 (2010).
74. Rényi I, Bárdi E, Udvardi E et al. Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non- Hodgkin's lymphoma. Pathol. Oncol. Res. 13(1), 57-62 (2007). (Pubitemid 46883548)
75. Pui CH, Jeha S, Irwin D et al. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 15(10), 1505-1509 (2001). (Pubitemid 32994667)
76. Browning LA, Kruse JA. Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann. Pharmacother. 39(11), 1932-1935 (2005). (Pubitemid 41527709)
77. Borinstein SC, Xu M, Hawkins DS. Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia. Pediatr. Blood Cancer 50(1), 189 (2008). (Pubitemid 350234303)
78. Pui CH. Rasburicase: a potent uricolytic agent. Exp. Opin. Pharmacother. 3(4), 433-442 (2002).
79. Davidson MB, Thakkar S, Hix JK et al. Pathophysiology, clinical consequences and treatment of tumor lysis syndrome. Am. J. Med. 116(8), 546-554 (2004). (Pubitemid 38452647)
80. Cheson BD, Dutcher BS. Managing malignancy-associated hyperuricemia with rasburicase. J. Supportive Oncol. 3, 117-124 (2005). (Pubitemid 40439754)
81. Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int. J. Med. Sci. 4(2), 83-93 (2007). (Pubitemid 46434125)
82. Annemans L, Moeremans K, Lamotte M et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support. Care Cancer 11(4), 249-257 (2003). (Pubitemid 36723571)
83. Candrilli S, Bell T, Irish W, Morris E, Goldman S, Cairo MS. Acomparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding hodgkin disease) associated with and without acute renal failure. Clin. Lymphoma Myeloma 8(1), 44-51 (2008). (Pubitemid 351449718)
84. Macfarlane RJ, McCully BJ, Ferandez CV. Rasburicase prevents tumor lysis syndrome despite extreme hyperleukocytosis. Pediatr. Nephrol. 19(8), 924-927 (2004). (Pubitemid 39144780)
85. Pui CH. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United Sates experience. Semin. Hematol. 38(Suppl. 10), S13-S21 (2001).
86. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J. Am. Soc. Nephrol. 19(12), 2407-2413 (2008).
87. Kanellis J, Watanabe S, Li JH et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41(6), 1287-1293 (2003). (Pubitemid 36706079)
88. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum. 50(8), 2400-2414 (2004). (Pubitemid 39066263)
89. Terkeltaub RA. Clinical practice. Gout. N. Engl. J. Med. 349(17), 1647-1655 (2003).
90. Perez-Ruiz F, Lioté F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum. 57(7), 1324-1328 (2007). (Pubitemid 47585481)
91. Perez-Ruiz F, Calabozo M, Herrero- Beites M, García-Erauskin G, Pijoan JI. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephrology 86(3), 287-291 (2000).
92. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am. J. Kidney Dis. 47(1), 51-59 (2006). (Pubitemid 41828266)
93. Band PR, Silverberg DS, Henderson JF et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N. Engl. J. Med. 283(7), 354-357 (1970).
94. LaRosa C, McMullen L, Bakdash S et al. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr. Nephrol. 22(1), 132-135 (2007). (Pubitemid 46138373)
95. Veenstra J, Krediet RT, Somers R, Arisz L. Tumour lysis syndrome and acute renal failure in Burkitt's lymphoma. Description of 2 cases and a review of the literature on prevention and management. Neth. J. Med. 45(5), 211-216 (1994). (Pubitemid 24340036)
96. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr. Nephrol. 9, 206-212 (1995).
97. Tosi P, Barosi G, Lazzaro C et al. Consensus conference on the management of tumor lysis syndrome. Haematologica 93(12), 1877-1885 (2008).
98. Kikuchi A, Kigasawa H, Tsurusawa M et al. Astudy of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome. Int. J. Hematol. 90(4), 492-500 (2009).
99. Wang LY, Shin LY, Chang H et al. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. Acta Haematol. 115(1-2), 35-38 (2006). (Pubitemid 43130430)
100. Ducros J, Saingra S, Rampal M, Coulange C, Barbe MC, Verzetti G. Haemolytic anaemia due to G6PD deficiency and urate oxidase in a kidney transplant patient. Clin. Nephrol. 35, 89-90 (1991).
101. Lorigan PC, Woodings PL, Morgenstern GR, Scarffe JH. Tumour lysis syndrome, case report and review of the literature. Ann. Oncol. 7(6), 631-636 (1996). (Pubitemid 26285645)
102. Sondheimer JH, Migdal SD. Toxic nephropathies. Crit. Care Clin. 3(4), 883-907 (1987).
103. Levine AM. Challenges in the management of Burkitt's lymphoma. Clin. Lymphoma 3(Suppl. 1), S19-S25 (2002).
104. Yim BT, Sims-McCallum RP, Chong PH. Rasburicase for the treatment and prevention of hyperuricemia. Ann. Pharmacother. 37(7-8), 1047-1054 (2003). (Pubitemid 36875239)
105. Hsu HH, Huang CC. Acute spontaneous tumor lysis in anaplastic large T-cell lymphoma presenting with hyperuricemic acute renal failure. Int. J. Hematol. 79(1), 48-51 (2004).